Antibody Discovery Platform
Our dedicated team of technical experts have engineered and constructed the Galaxy® antibody library that underpins our proprietary platform. Based on the principle of ‘smart randomness’, our Galaxy® library harnesses the incredible diversity found within human B cells in a focused way, maximising the proportion of correctly folded functional antibodies.
This leads to a higher-quality, functionally diverse starting repertoire that prioritises quality from the beginning. Our ‘Glass Spleen’ approach incorporates the learnings of the in vivo selection process, allowing us to access a far greater fraction of relevant antibody space. This process results in potent antibodies without the need for excessive mutational load.
Low-risk, targeted diversification
B cell-like evolution
Controlled Light Chain Diversity
Diverse, but predictable
Antibody drug discovery services for rapid generation of world-class biologics with optimal drug development qualities.
RxBiologics Galaxy® is a registered trademark in the United Kingdom
B950 Dorothy Hodgkin Building,
Babraham Research Campus,
Babraham, Cambridge CB22 3FH